Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine in Pediatric Tourette Syndrome
NCT03530293Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of valbenazine in Tourette syndrome (TS), sponsored by Neurocrine Biosciences. Started Apr 2018; status: terminated.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03530293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530293.